Skip to content
    NTLA
    Earnings call· Jun 2026(Q2 FY26)

    Intellia Therapeutics Q2 FY26 earnings call NTLA

    Aug 6, 2026 Source

    Executive summary

    Intellia Therapeutics Q2 FY26 — Positive Lonvo-z Phase III Results and Nex-z Clinical Progress

    Intellia Therapeutics reported strong Q2 FY26 results, highlighted by positive Phase III data for lonvo-z in HAE, positioning it for a potential H1 2027 launch. The company also resumed enrollment in its nex-z ATTR trials and identified a genetic marker for transaminase elevations, enhancing patient management. Financials reflect ongoing R&D and commercial build-out, with a solid cash runway.

    Highlights

    5
    • Lonvo-z Phase III HAELO trial achieved statistical significance for the primary and all key secondary endpoints, demonstrating an 87% reduction in mean monthly HAE attacks versus placebo.

    • 62% of patients in the lonvo-z arm were entirely attack-free and therapy-free during the 6-month primary observation period.

    • Nex-z Phase III trials (MAGNITUDE) resumed enrollment and dosing in Q2 FY26, with screening rates rapidly increasing globally.

    • Identified a specific HLA allele (C*05:01) associated with higher-grade transaminase elevations for nex-z, providing a mechanistic explanation and a tool for patient identification.

    • Cash, cash equivalents, and marketable securities were $628.4 million as of June 30, 2026, providing a cash runway into 2028, excluding product revenues.

    Concerns

    3
    • Net loss for Q2 FY26 was $106.6 million, compared to $101.3 million for the prior year quarter.

    • Collaboration revenue decreased to $7.7 million for Q2 FY26 from $14.2 million for the prior year quarter, primarily due to a reduction from Regeneron.

    • Grade 4 liver transaminase elevations were observed in less than 1% of nex-z patients, with a specific HLA allele (C*05:01) identified as a risk factor for higher-grade elevations.

    Guidance & targets

    4
    CategoryTargetConfidence
    Lonvo-z BLA acceptance
    FDA acceptance
    high materiality
    High
    Lonvo-z U.S. launch
    U.S. launch
    high materiality
    High
    Cash runway
    Into 2028
    high materiality
    High
    MAGNITUDE-2 enrollment completion
    Completion of enrollment
    medium materiality
    High

    Operational metrics

    10
    Equity financing net proceeds
    $195 million
    Q2 FY26

    Net proceeds from an equity financing completed in April 2026.

    Cash, cash equivalents and marketable securities
    $628.4 millionvs $605.1 million on Dec 31, 2025
    Q2 FY26

    Cash balance as of June 30, 2026, providing runway into 2028.

    Collaboration revenue
    $7.7 millionvs $14.2 million for Q2 FY25
    Q2 FY26

    Primarily due to a reduction in revenue from Regeneron.

    R&D expenses
    $82.6 millionvs $97 million for Q2 FY25
    Q2 FY26

    Decrease primarily driven by lower external costs related to lonvo-z and nex-z and reduced stock-based compensation, partially offset by higher employee-related expenses.

    Stock-based compensation expense (R&D)
    $9.4 million
    Q2 FY26

    Included in R&D expenses.

    G&A expenses
    $37.8 millionvs $27.2 million for Q2 FY25
    Q2 FY26

    Increase primarily driven by costs associated with commercial infrastructure build-out, higher legal expenses, and stock-based compensation.

    Stock-based compensation expense (G&A)
    $8.6 million
    Q2 FY26

    Included in G&A expenses.

    Net loss
    $106.6 millionvs $101.3 million for Q2 FY25
    Q2 FY26

    Net loss for the second quarter.

    Nex-z HLA C*05:01 allele prevalence
    12%
    Across all nex-z clinical trials

    Prevalence of the specific HLA allele associated with higher-grade transaminase elevations.

    MAGNITUDE patients enrolled
    >650
    To date

    Number of patients enrolled in the MAGNITUDE trial for nex-z.

    Industry KPIs

    4
    MetricValueDetails
    Pipeline read out calendarEnrollment completion
    Regulatory approvals filingsBLA submission underway
    Clinical trial efficacy safety data87% reduction in mean monthly attacks%
    Collaboration milestone royalty revenue$7.7 millionUSD

    Product announcements

    1
    ProductTypeDetails
    haereframed.comlaunch

    Risks & headwinds

    2
    Grade 4 liver transaminase elevations in nex-z patients2 to 5 weeks after dosing (for elevations)

    Observed in less than 1% of patients; specific HLA allele C*05:01 identified as a risk factor for higher-grade elevations (12% prevalence in samples analyzed).

    Mitigation: Implemented mitigation measures to enhance monitoring and intervention; updated protocols, investigators' brochures, and informed consents to incorporate HLA typing for all Phase III patients; engaging with FDA to review findings.

    Disappointing top-line results from CARDIO-TTRansform trial (eplontersen)About a month ago (reported)

    Disappointing top-line results shared from CARDIO-TTRansform, a pivotal trial of a TTR silencer for ATTR cardiomyopathy.

    Mitigation: Intellia believes the negative outcome is specific to eplontersen and does not speak to combination outcomes in general, maintaining belief that combination therapy will work with the right agent. Will review detailed data at ESC and consider optimizing MAGNITUDE's design.

    What to watch in Q3 FY26

    5

    Lonvo-z BLA acceptance

    End of 2026
    CurrentRolling BLA submission underway
    TargetFDA acceptance

    Why it matters

    Key regulatory milestone for the world's first in vivo gene editing product, impacting potential launch timelines.

    we expect to be in a position to announce the FDA's acceptance of a BLA filing for lonvo-z by the end of this year.

    Q&A highlights

    8

    What are the implications of the C*05:01 allele finding for the 12% of patients at added risk? Are there other parameters for patient selection, and what is the biologic relationship triggering the immune response?

    The finding confirms an adaptive immune response, supporting current mitigation measures. Information on the allele will be provided to investigators and patients, allowing them to make informed decisions. Many C*05:01 carriers do not experience elevations, but the allele increases the likelihood of severe events. The company will discuss further implications with the FDA.

    What the finding gives us is valuable, a mechanistic explanation for a general signal we had already flagged and a way to identify patients who are more likely to be affected before it happens.

    asked by Maurice Raycroft · answered by John Leonard

    3 min read6 chapters

    Detailed Narrative

    01

    Lonvo-z HAELO Trial Success and NEJM Publication

    Intellia reported positive top-line results from the Phase III HAELO trial for lonvo-z in hereditary angioedema (HAE), achieving statistical significance for the primary and all key secondary endpoints. The trial demonstrated an 87% reduction in mean monthly attacks versus placebo, with 62% of patients being attack-free and therapy-free during the 6-month observation period. A 23-point improvement in the angioedema quality of life score was observed, significantly exceeding the clinically meaningful threshold of 6 points. These results were published in the New England Journal of Medicine, highlighting the unique value proposition of this one-time📎 treatment.

    02

    Lonvo-z Commercial Readiness and Disease Awareness

    The company is actively advancing its pre-commercial readiness efforts for a potential U.S. launch of lonvo-z in the first half of 2027. This includes hiring field medical, reimbursement, and strategic accounts teams who are engaging with treatment centers. Intellia also launched haereframed.com, a disease awareness initiative, to educate about the burdens of HAE and the potential benefits of a one-time📎 therapy like lonvo-z, contrasting it with lifelong chronic treatments.

    03

    Nex-z Clinical Trial Resumption and TTR Knockdown Profile

    Enrollment and dosing in the Phase III MAGNITUDE trials for nex-z in ATTR cardiomyopathy and polyneuropathy resumed in Q2 FY26 after clinical holds were resolved. Investigator engagement remains high, and screening rates are rapidly increasing. Nex-z has demonstrated an unsurpassed mean TTR reduction of 90% in Phase I data, achieving mean serum TTR levels below 20 micrograms per milliliter within one month, which is significantly lower than leading chronic silencers. This knockdown was consistent across all patients and maintained long-term.

    04

    Nex-z HLA Allele Finding and Mitigation Strategy

    Intellia identified a specific HLA allele, C*05:01, as being associated with a significantly higher rate of Grade 3 or greater transaminase elevations in nex-z clinical trials. This finding provides a mechanistic explanation for previously observed transient📎 elevations and allows for identification of potentially susceptible patients. While only 12% of patients carry this allele and most carriers do not experience severe elevations, the company has updated protocols to include HLA typing for all Phase III patients, informing treatment decisions and enhancing confidence in the benefit-risk profile.

    05

    ATTR Market Dynamics and MAGNITUDE Trial Design

    The company discussed the large and growing ATTR market, noting recent disappointing top-line results from the CARDIO-TTRansform trial for eplontersen. Intellia believes these results are specific to eplontersen and do not negate the potential for combination therapy with the right agent, emphasizing nex-z's superior TTR knockdown. The MAGNITUDE trial, which has enrolled over 650 patients, is event-based, and the blinded event rate remains within projected ranges. The company plans to review detailed CARDIO-TTRansform data to consider potential optimizations for MAGNITUDE's design.

    06

    Financial Overview and Equity Financing

    Intellia completed an equity financing in April 2026, yielding approximately $195 million in net proceeds. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $628.4 million, providing a runway into 2028, conservatively excluding future product revenues. Collaboration revenue for Q2 FY26 was $7.7 million, down from $14.2 million in the prior year, primarily due to reduced revenue from Regeneron. R&D expenses decreased to $82.6 million, while G&A expenses increased to $37.8 million, driven by commercial infrastructure build-out and legal costs.

    AI-generated summary of the company’s earnings call. Not investment advice.